Jade Biosciences, Inc. Debt Securities, Available-for-sale, Amortized Cost
Jade Biosciences, Inc. (JBIO) had Debt Securities, Available-for-sale, Amortized Cost of $125.32 million as of 2022-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2022-08-15
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost $125.32M.
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $133.58M.
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost $113.24M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2022-06-30 | $125.32M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $133.58M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $113.24M 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |